Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations / 临床肝胆病杂志

ABSTRACT

ObjectiveTo investigate the clinical effect and safety of percutaneous radiofrequency ablation (RFA) following transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer in high-risk locations. MethodsThe patients with primary liver cancer in high-risk locations who were diagnosed and treated from January 2011 to December 2015 were enrolled. All the patients underwent TACE followed by CT-guided RFA 3-5 days later. The treatment outcome and adverse events were observed. ResultsA total of 64 patients with 76 lesions were enrolled and all of them completed TACE and RFA. At one month after surgery, the complete tumor ablation rate was 81.5% (62/76). The patients were followed up for 6 to 64 months after surgery; at the end of follow-up, the local tumor progression rate was 28.9% (22/76), and the 1-, 2-, and 3-year survival rates were 90.6%, 78.1%, and 64.1%, respectively. The incidence rate of severe surgical complications during follow-up was 3.1% (one patient each experienced liver abscess and hematobilia), and the patients achieved remission after medical treatment and interventional treatment without any sequel. ConclusionCT-guided RFA after TACE is a safe and feasible regimen for primary liver cancer in high-risk locations.